| There are four identified types of thyroid carcinoma,including papillary thyroid carcinoma(PTC),follicular carcinoma,medullary carcinoma and undifferentiated carcinoma.PTC is the most common type,which is about 85% of the total thyroid carcinoma[1].PTC has relatively better prognosis and lower death rate,while the high morbidity,high relapse rate,high risk of distant metastasis rate and high malignant metastasis rate makes the treatment of PTC one of the most difficult medicalproblems [1,2].Cellular level study result has proved,PTC derives from follicular epithelial cells,especially the thyroid follicular cells.Today,diagnosis of PTC is mostly histopathological examination of thyroid tissue combined with individual clinical data.While recently,the limitation of fine needle aspiration biopsy is uncovered,improper operation of needle aspiration and cell shedding caused by hardening of the tumor tissue will lead to the escape of PTC.Poor recognition of PTC cells will directly affect the diagnosis results too.Based on a roughly statistical data,30% of the biopsy before surgery is under detected[3,4].Therefore,it is of great clinical significance to find the effective molecular biomarkers of PTC,which will also help to improve personalized therapy and avoid unnecessary surgery.In recent years,there are extensive reports on the abnormal expression of mi RNAs in human cancer tissues,especially PTC.Early studies focused on the histopathology,gene level and protein level,explored the abnormal expression of miRNAs in PTC,compared with normal tissues.Thease work has made achievements,for example,compared with normal tissues,miRNA-21,miRNA-146 b,miRNA-221,miRNA-222 and miRNA-31 has higher expression level in PTC[5,6,7].Compared with normal PTC,the expression of miRNA-138 and miRNA-98 was lower in aggressive PTC[8].However,due to the limitations of experimental techniques and materials,some conclusions are even contradictory.Thus,with the help of appropriate research methods,the acurate experimental material sampling etc,we will explore specific miRNAs in PTC from new perspective,provides experimental basis and theoretical basisfor the future targeted therapy.MiRNA-106 a is a oncogenes,which is identified high expression level in esophageal cancer[9],gastric cancer[10],colorectal cancer[11,12],lung cancer[13] and other cancer tissues.Based on the research data,over expression of miRNA-106 a could enhance the development of tumor by promoting the proliferation of tumor cells,inhibiting the apoptosis of tumor cells and inducing tumor angiogenesis.These studies provided firmly fact that miRNA-106 a plays an important role in cancer development.However,so far,there is no deep studies on the occurrence and development of PTC.This study will provide experimental basis for miRNA-106 a gene therapy for PTC,and will provide new thoughts and a clear direction for the future study in the mechanism of miRNA-106 a.Objective: To discover and judge their mportant roles of miRNA-106 a in PTC,support the hypothesis of miRNA-106 a as biomarker of PTC diagnosis and prognosis,and provide arguments for targeted gene treatment.Methods:Detect the expression level of miRNA-106 a in tumor tissues,adjacent normal tissues and thyroid adenoma tissues from PTC patients,and detectmiRNA-106a's expression level in plasma of patients with PTC,thyroid adenoma and healthy volunteers.Discuss the clinical value of miRNA-106 a in diagnosis and prognosis of PTC in different levels.(1)Determine the tissue specificity of miRNA-106 a expression30 cases specimens were collected from PTC patients in Shanghai 8th People's Hospital,including tumor tissues,adjacent normal tissues and thyroid adenoma.Detect content of miRNA-106 a in the tissue with q RT-PCR(quantitative real-time polymerase chain reaction)method.Specify the distribution of miRNA-106 a expression in different tissues and its relationship with the clinicopathological features of PTC.(2)Determinethe Plasma characteristics of miRNA-106 a expressionPlasma specimens from PTC patient,patients with thyroid adenoma and health people,each 28 cases were collected,deteceted the expression level of miRNA-106 a in the plasma with qRT-PCR method.Study the relationship between the expression of miRNA-106 a in tissues and plasma.Specify miRNA-106a's expression in plasma and its relationship with the clinicopathological features of PTC patients.Results:(1)The relative expression of miRNA-106 a in PTC tissues and adjacent normal tissues and thyroid adenoma tissues were 3.63±0.36,1.04±0.08 and 1.71±0.48.The expression level of mi RNA-106 a in PTC tissues was significantly higher than that in adjacent normal tissues and thyroid adenoma(P <0.01).(2)The relative expression level of miRNA-106 a in plasma of patients with PTC,thyroid adenoma and healthy volunteers was 4.4±0.135,2.5±0.058 1.00±0.062 respectively.The expression level of miRNA-106 a in plasma of patients with PTC was significantly higher than that in patients with thyroid adenoma(P < 0.001).The expression of mi RNA-106 a in plasma of PTC group was significantly higher than that of healthy subjects(P < 0.001).Conclusion:(1)The aberrant upregulation of miRNA-106 a in PTC tissues and plasma should has close relationship with the morbidity and progress of PTC.(2)Plasma miRNA-106 a could be a new biomarkerin the diagnosis and prognosis of PTC. |
PDF Full Text Request